US2015320743A1PendingUtilityA1
Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
Est. expiryMay 29, 2029(~2.8 yrs left)· nominal 20-yr term from priority
A61P 7/04A61P 43/00A61P 29/00A61L 2300/40A61L 2300/204A61K 9/0014A61P 17/00A61K 31/167A61K 31/498A61L 2400/06A61K 31/00A61L 2300/402A61K 31/728A61P 17/02A61L 27/20A61K 45/06A61K 38/164A61L 27/54A61K 9/08
32
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An injectable composition for treating a skin defect comprising:
i. hyaluronic acid (HA); ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
2 . The composition of claim 1 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
3 . The composition of claim 2 , wherein the α2-adrenergic receptor agonist is brimonidine.
4 . The composition of claim 1 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.
5 . The composition of claim 1 , wherein the HA represents 1% to 2.5% by weight of the composition.
6 . The composition of claim 1 wherein the lidocaine or the pharmaceutically acceptable salt thereof represents 0.01% to 3% by weight of the composition.
7 . A kit comprising at least one syringe and the composition of claim 1 .
8 . A method for treating a skin defect comprising the step of injecting simultaneously an individual in need thereof with:
i. hyaluronic acid (HA); ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
9 . The method of claim 8 wherein the skin defect is a fold, wrinkle, skin depression or scar.
10 . The method of claim 8 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
11 . The method of claim 10 , wherein the α2-adrenergic receptor agonist is brimonidine.
12 . The method of claim 8 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.
13 . A method for diminishing, decreasing or avoiding a skin reaction in an individual due to injection of a dermal filler, comprising the step of injecting simultaneously:
i. hyaluronic acid (HA); ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
14 . The method of claim 13 wherein the skin reaction due to injection is redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
15 . The method of claim 13 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
16 . The method of claim 15 , wherein the α2-adrenergic receptor agonist is brimonidine.
17 . The method of claim 13 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.
18 . An injectable composition for treating a skin defect comprising:
i. a botulinum toxin; ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
19 . The composition of claim 18 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
20 . The composition of claim 19 , wherein the α2-adrenergic receptor agonist is brimonidine.
21 . The composition of claim 18 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.
22 . The composition of claim 18 wherein the lidocaine or the pharmaceutically acceptable salt thereof represents 0.01% to 3% by weight of the composition.
23 . A kit comprising at least one syringe and the composition of claim 18 .
24 . A method for treating a skin defect comprising the step of injecting simultaneously an individual in need thereof with:
i. a botulinum toxin; ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
25 . The method of claim 24 wherein the skin defect is a fold, wrinkle, skin depression or scar.
26 . The method of claim 24 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
27 . The method of claim 26 , wherein the α2-adrenergic receptor agonist is brimonidine.
28 . The method of claim 24 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.
29 . A method for diminishing, decreasing or avoiding a skin reaction in an individual due to injection of a dermal filler, comprising the step of injecting simultaneously:
i. a botulinum toxin; ii. an α-adrenergic receptor agonist; and iii an anaesthetic, wherein the anaesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
30 . The method of claim 29 wherein the skin reaction due to injection is redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
31 . The method of claim 29 , wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist.
32 . The method of claim 31 , wherein the α2-adrenergic receptor agonist is brimonidine.
33 . The method of claim 29 , wherein the α-adrenergic receptor agonist is brimonidine, xylometazoline, or oxymetazoline.Join the waitlist — get patent alerts
Track US2015320743A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.